42.82
-0.12(-0.28%)
Currency In USD
| Previous Close | 42.94 |
| Open | 42.53 |
| Day High | 43.48 |
| Day Low | 42.05 |
| 52-Week High | 62.53 |
| 52-Week Low | 24.1 |
| Volume | 1.87M |
| Average Volume | 1.55M |
| Market Cap | 4.06B |
| PE | -9.45 |
| EPS | -4.53 |
| Moving Average 50 Days | 40.01 |
| Moving Average 200 Days | 34.04 |
| Change | -0.12 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $1,747.04 as of November 13, 2025 at a share price of $42.82. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $3,324.53 as of November 13, 2025 at a share price of $42.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Nov 10, 2025 9:28 PM GMT
SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an agg
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
GlobeNewswire Inc.
Oct 23, 2025 12:00 PM GMT
Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effectsSAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cr
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Oct 10, 2025 8:41 PM GMT
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggr